Article
Predictors of Hand-Foot Syndrome and Pyridoxine for Prevention of Capecitabine-Induced Hand-Foot Syndrome: A Randomized Clinical Trial.
JAMA oncology - 1 Nov 2017
Yap Yoon-Sim, Kwok Li-Lian, Syn Nicholas, Chay Wen Yee, Chia John Whay Kuang, Tham Chee Kian, Wong Nan Soon, Lo Soo Kien, Dent Rebecca Alexandra, Tan Sili, Mok Zuan Yu, Koh King Xin, Toh Han Chong, Koo Wen Hsin, Loh Marie, Ng Raymond Chee Hui, Choo Su Pin, Soong Richie Chuan Teck
Abstract excerpt
IMPORTANCE: Hand-foot syndrome (HFS) is a common adverse effect of capecitabine treatment. OBJECTIVE: To compare the incidence and time to onset of grade 2 or greater HFS in patients receiving pyridoxine vs placebo and to identify biomarkers predictive of HFS. DESIGN, SETTING, AND PARTICIPANTS: This single-center, randomized double-blind, placebo-controlled phase 3 trial conducted at National Cancer Centre...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
